Search DIAN Tissue Requests
In order to avoid the situation where two investigators study the same research question, please search our database to determine if your topic has already been studied. If you find that your topic or a related topic has already been submitted, you may wish to contact the investigator to inquire about his/her findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID # (e.g. DIAN-T1004), the full request has been submitted and is either approved, disapproved or in process.
Sto mostrando 1 - 10 di 80
VE-cadherin in Alzheimer Disease
Examine the diagnostic value of CSF and plasma levels of VE-cadherin as a marker of vascular injury in EOAD
Investigate whether VE-cadherin correlates with CSF and imaging measures of amyloid, tau, brain atrophy, and glucose hypometabolism in EOAD in cross-sectional and longitudinal analyses
Determine whether baseline VE-cadherin levels influences age of onset or rate of cognitive decline in asymptomatic and symptomatic mutation carriers
Metabolomic and lipidomics changes in ADAD
Determine metabolite signatures of ADAD
Identify locus-metabolite and lipids associations via Metabolite genome-wide association studies (M-GWAS).
Measurement of glial fibrillary acidic protein (GFAP) levels in blood for evaluation of astrocyte reaction in Alzheimer disease.
Determine trajectory of GFAP over the ADAD disease course in relation to amyloid
Add-on DIAN project 3 Novel mechanisms: pilot OLINK proteomics in left-over CSF aliquots
Study which OLINK proteins (signature) are discriminative between ADAD and controls
Compare with sporadi AD
Compare with Mass Spec in ADAD
TEST BIO SUBMISSION
test the form
test the form 2
test the form 3
test the form 4
Plasma cell-free RNA as non-invasive biomarker for neurodegeneration
Validate genomic models for disease pathology in Autosomal Dominant Alzheimer
Develop a specific predictive model for ADAD
Identification and validation of novel AD biomarkers for clinical development of Eisai AD pipelines
To profile of CSF MTBR-tau isoforms which can be captured by E2814 across all DIAD stages using CSF samples from DIAN-observation cohort.
1) Dr. Alison M. Goate, 2) Dr. Sarah M. Neuner
Defining the role of microglia in Alzheimer’s disease risk and resilience
Aim 1: Investigate the effect of high-risk or protective amyloid precursor protein (APP) mutations on microglia cell function.
Optimization of a blood diagnosis of the silent phase of Alzheimer's disease
Confirm the performance of a diagnostic algorithm developed on European plasma samples.
Improve the algorithm by learning on human plasma samples of more varied genetic origin and environmental background.
Improve the algorithm by learning on human plasma samples collected longer before the diagnosis of Alzheimer's disease.
Apolipoprotein E isoform levels and their relevance to the development of AD pathology
By use of mass-spectrometry assess and compare the individual apolipoprotein E isoform levels in plasma and CSF from familial AD patients versus controls
To investigate whether fluid levels of apolipoprotein E are related to the estimated year of disease onset, CSF and imaging AD biomarkers in familial AD patients
To elucidate a potential correlation between plasma apolipoprotein E levels and previously assessed CSF alpha-synuclein levels whereof the latter appeared related to amyloid-beta deposition and symptom onset